Configure the table properties Dosage and administration In the Phase 3 VALOR clinical trial, brepocitinib was administered orally once daily at a dose of 15 mg or 30 mg for 52 weeks. Place in...

cover image for summer 2025 New therapies, payer strategies and pipeline updates shaping the future of managed care  Prime Therapeutics /summer-2025-prime-therapeutics-report The Prime Therapeutics...

denecimig (Mim8) - Hematologic The Deep dive section features an analysis for select pipeline drugs that are expected to be FDA-approved in the upcoming quarters. Selected agents are expected to...

Cover image for Summer 2024 Prime Therapeutics Report Pulmonary arterial hypertension: Exciting new approval and payer impact Prime Therapeutics /2024-summer-prime-therapeutics-report The Prime...